Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome

David Currow, Amy Abernethy

    Research output: Contribution to journalArticlepeer-review

    23 Citations (Scopus)

    Abstract

    Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia.

    Original languageEnglish
    Pages (from-to)789-802
    Number of pages14
    JournalFuture Oncology
    Volume10
    Issue number5
    DOIs
    Publication statusPublished - Apr 2014

    Keywords

    • anamorelin HCl
    • body weight
    • cancer anorexia-cachexia syndrome
    • ghrelin receptor agonist
    • handgrip strength
    • lean body mass

    Fingerprint Dive into the research topics of 'Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome'. Together they form a unique fingerprint.

    Cite this